Nanologica AB (SE:NICA)
:NICA
Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.33 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr65.45M
Enterprise Valuekr64.94M
Total Cash (Recent Filing)kr3.55M
Total Debt (Recent Filing)kr21.47M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding109,823,600
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr83.10M
Bulls Say, Bears Say
Bulls Say
Pharma Consumable Business ModelSelling silica-based separation media into pharmaceutical R&D and manufacturing creates a consumable, repeatable revenue stream. Structural demand for validated separation materials and recurring lab/manufacturing use can support predictable order cadence and customer stickiness over months.
Top-line Growth Vs Prior YearMeaningful revenue expansion year-over-year indicates improving product adoption or market traction. Sustained top-line growth provides the scale needed to absorb fixed costs and offers a path to improving unit economics if the company continues to expand sales and operational leverage.
Improving Cash-burn TrendOperating cash outflows have meaningfully narrowed year-over-year, indicating better cost control or revenue mix. A continued reduction in cash burn enhances runway and increases the chance of reaching break-even without immediate dilutive financing, improving medium-term resilience.
Bears Say
Negative Gross Profit And LossesA negative gross profit means the core product economics are currently unprofitable, so every incremental sale worsens cash needs until unit costs or pricing change. Persistent operating losses prevent internal funding of growth and require structural improvements to margins to attain sustainability.
Persistent Free Cash Flow BurnSustained negative operating and free cash flow forces reliance on external capital and increases dilution risk. Continued cash consumption limits the firm's ability to invest in scaling production, commercialization, or R&D, impairing the company's ability to convert revenue momentum into profitability.
Eroded Equity CushionA steep reduction in shareholders' equity weakens the firm's ability to absorb future losses or take on additional borrowing. This degradation increases the likelihood of future capital raises on dilutive terms and reduces financial flexibility for strategic initiatives over the medium term.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.33 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr65.45M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is May 20, 2026 which is in 19 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Feb 26, 2026. The company reported -kr0.188 earnings per share for the quarter, missing the consensus estimate of -kr0.099 by -kr0.089.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 109,823,600 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -kr0.188 in its last earnings report, missing expectations of -kr0.099. Following the earnings report the stock price went up 7.104%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―